(Q39286854)

10 September 2017

Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells (English)

1 reference

10 September 2017

1 reference

ChEBI release 2020-05-28

ChEBI ID

90295

multiple drug resistance

1 reference

Ki-Hwan Eum

1

1 reference

10 September 2017

Soon Kil Ahn

series ordinal

2

1 reference

10 September 2017

Hara Kang

series ordinal

3

1 reference

10 September 2017

Michael Lee

series ordinal

4

1 reference

10 September 2017

language of work or name

1 reference

2 September 2012

1 reference

Molecular and Cellular Biochemistry

10 September 2017

1 reference

10 September 2017

372

1 reference

10 September 2017

1-2

1 reference

10 September 2017

65-74

1 reference

https://scigraph.springernature.com/pub.10.1007/s11010-012-1446-0

10 September 2017

0 references

cites work

Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Hyperactive Ras in developmental disorders and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Sorafenib for the treatment of advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Mechanisms of cancer drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

The enhancement of Raf-1 kinase activity by knockdown of Spry2 is associated with high sensitivity to paclitaxel in v-Ha-ras-transformed NIH 3T3 fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Targeting the autophagy pathway using ectopic expression of Beclin 1 in combination with rapamycin in drug-resistant v-Ha-ras-transformed NIH 3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

IAP proteins: blocking the road to death's door

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

TOR, a central controller of cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Regulation and role of Raf-1/B-Raf heterodimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Inhibition of macroautophagy triggers apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Reversal effect of Raf-1/Mdr-1 siRNAs co-transfection on multidrug resistance in KBv200 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-012-1446-0

Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38- cells

21 January 2018

1 reference

12 December 2020

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin.

1 reference

12 December 2020

FDA approves sorafenib for patients with inoperable liver cancer

1 reference

12 December 2020

Oncogenic BRAF is required for tumor growth and maintenance in melanoma models

1 reference

12 December 2020

Reversion of drug-resistant hepatocellular carcinoma cell line BEL-7402/FU by sorafenib

1 reference

12 December 2020

10.1007/S11010-012-1446-0

Identifiers

DOI

1 reference

10 September 2017

1 reference